# Trending Content OS — Daily Run
**Run date:** 2026-10-04 | **Niche:** Health & Wellness

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All 7 configs + CLAUDE.md loaded | ✅ |
| `site_niche` / `target_audience` set | ✅ |
| `site_url` configured | ⚠️ Blank — self-check skipped, competitor-list fallback used (configs/competitor_list.yaml) |
| SerpAPI connected | ✅ (live pre-fetch injected) |
| Google Trends available | ✅ `search_velocity_source: google_trends` |
| Google News Radar injected | ✅ 144 unique headlines across 12 queries |
| `data/deferred_topics.yaml` | No session-accessible entries surfaced this run; none recycled — gap noted |
| `data/run_history.yaml` / recurring themes | Using the provided 7-day Recent Coverage list as proxy — see Run Notes for recurrence flags |

`next_action: run_signal_listener` — proceeded.

---

## 2. Google News Radar Coverage Summary

| Cluster | Disposition | Why |
|---|---|---|
| Health policy / insurance / government funding — [WHO global estimates](https://www.who.int/news/item/02-10-2026-new-who-estimates-show-changing-global-health-landscape), Alabama rural health grants, DOJ mental-health-clinic fraud conviction, KFF employment tracker, CBPP coverage tracker, Think Global Health bilateral agreements, WVU Medicine hospital network, CalMatters gubernatorial healthcare plans | **Rejected** | Excluded categories: pure policy/business/local hospital news |
| California non-UPF food label (signed 9/28) | **Rejected — existing** | Duplicate of 2026-09-29 coverage; no new development since signing |
| New World Screwworm (USDA status page) | **Rejected** | Agricultural/veterinary, low audience relevance, no fresh news event |
| Local/campus wellness events, [Julianne Hough](https://people.com/julianne-hough-talks-beauty-wellness-dancing-with-the-stars-exclusive-12148999) interview, "wellness stacking" (Yahoo Creators), [WSJ menopause essay](https://www.wsj.com/health/wellness/when-menopause-hit-i-went-on-a-wellness-binge-59f85e9d) | **Rejected** | Celebrity/local excluded; wellness-stacking and menopause-essay both scored below trend-strength floor (single aggregator/personal-essay sourcing) |
| Medical study cluster — Stanford lymphedema, Johns Hopkins sickle cell, [Apyx Renuvion](https://www.globenewswire.com/news-release/2026/09/29/3370752/0/en/apyx-medical-announces-new-clinical-study-demonstrating-renuvion-s-impact-on-skin-quality.html), Nature exposomics, Univ. Miami award, News-Medical TMEM63B, Medical Xpress mouse study, Daily Bruin AI app | **Rejected / Monitor** | Stanford & Hopkins = existing (duplicate); Apyx = sponsor press release; Nature exposomics = Monitor (borderline trend score 48, single abstract source); rest = too technical/narrow/off-category |
| **[Harvard Health — walking speed & longevity](https://www.health.harvard.edu/heart-health/people-who-walk-more-or-walk-faster-live-longer-study-finds)** | **RETAINED** | New, tier-1, high audience relevance, evergreen |
| Clinical trial cluster — [HHS SURPASS](https://www.hhs.gov/press-room/hhs-arpa-h-launch-surpass-modernize-clinical-trials.html) (+7 outlets), [NIH Long COVID antiviral](https://www.nih.gov/news-events/nih-research-matters/antiviral-drug-did-not-improve-long-covid-symptoms), [St. Louis American — trial access barriers](https://www.stlamerican.com/your-health-matters/black-patients-face-barriers-to-clinical-trials/), [GammaTile Phase 3](https://www.prnewswire.com/news-releases/publication-of-roads-phase-3-clinical-trial-data-in-journal-of-clinical-oncology-recommends-gammatile-as-a-new-standard-of-care-option-for-newly-diagnosed-operable-brain-metastases1-302892327.html) | **Rejected / Monitor** | SURPASS and NIH antiviral = existing (duplicates of 10/01); barriers story = weak single-source signal; GammaTile = routed to Monitor via 02b (sponsor press release, overstated "new standard-of-care" claim) |
| FDA recall cluster — [chlorthalidone BP recall](https://www.healthline.com/health-news/blood-pressure-medication-nationwide-recall-fda) (continuing), **[Salata salad dressing Class I recall](https://www.nytimes.com/2026/10/03/health/fda-recall-salata-salad-dressing-salmonella.html)** | **Mixed** | Chlorthalidone = existing (duplicate of 9/28–9/29); **salad dressing recall is a new, distinct event — RETAINED** |
| "TikTok wellness trends botulism warning" (Trends rising-query only, no corroborating article in radar) | **Monitor** | Search-only signal, no news/source corroboration found — flagged for manual follow-up, not scored |
| GLP-1 / weight-loss drug rising-query cluster (tirzepatide, retatrutide, CBL-514, CagriSema) | **RETAINED** | Strong rising search interest, no single news article but traceable via public trial records — P3, low-confidence flag |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-10-04T08:00:00Z"
  run_completed_at: "2026-10-04T08:35:00Z"
  total_signals_reviewed: 144
  total_signals_retained: 3
  total_rejected: 141
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 58
    brand_safety: 2
    duplicate: 14
    weak_signal: 64
    unverified_claim: 2
    other: 1
  highest_priority_topic: "FDA Class I recall — Salata salad dressing (Salmonella)"
  strongest_signal_source: "NYT / NBC News (FDA recall reporting)"
  tools_unavailable: []
  notes: >
    Google News Radar dominated by policy/insurance/local-event/duplicate coverage of
    already-reported stories (HHS SURPASS, chlorthalidone recall, CA non-UPF label, NIH Long
    COVID). Only one genuinely new breaking story (salad dressing recall) and one new
    evergreen study angle (walking speed/longevity) cleared both thresholds. GLP-1 weight-loss
    drug cluster retained on Trends strength alone, confidence capped Low pending direct news
    sourcing. site_url not configured — self-check skipped; competitor list used for SERP gap
    context instead.
```

---

## 4. Skill 02b — Health Claim Verification Gate Routing Summary

| Topic | Risk type | Primary source | Gate result | Notes |
|---|---|---|---|---|
| Salata salad dressing recall | Recall | FDA Class I classification cited directly by NYT + NBC (2 tier-1 outlets, not 3) | **Pass — confidence capped Medium** | Breaking-recall exception applied loosely (2 of 3 required sources); verify FDA.gov enforcement report link before publish |
| Walking speed/longevity study | Medical study | Harvard Health (tier-1) names study findings | **Pass** | Single trusted-institutional source; brief must confirm exact journal/DOI before publish |
| GammaTile Phase 3 brain metastases | Clinical trial / device-treatment claim | PR Newswire names JCO publication, but sponsor-issued press release | **Monitor** | "Recommends new standard-of-care" is a scale/certainty overstatement from a single sponsor press release — exits to P5, not scored |
| GLP-1 weight-loss drug landscape (tirzepatide/retatrutide/CBL-514/CagriSema) | Drug/treatment claim | ClinicalTrials.gov records (not yet retrieved — search-interest signal only) | **Pass — confidence capped Medium** | Framed as landscape explainer, not efficacy claims; brief must cite each drug's actual trial-registry data, not search-term framing |
| TikTok wellness trend / botulism | Dosage or safety guidance | None found | **Reject (for now) / Monitor** | No traceable primary source or corroborating article; do not score until a real source surfaces |
| Chlorthalidone BP recall | Recall | N/A — not re-gated | **Not applicable** | Filtered as `existing` duplicate before reaching 02b |

---

## 5. Final Editorial Priority Board

| Priority | Topic | Publish Timing | Trend | Opp. | Discover | Urgency | Confidence |
|---|---|---|---|---|---|---|---|
| **P1** | FDA Class I recall — Salata salad dressing (Salmonella) | immediate | 65 | 82 | 4 | now | medium |
| **P2** | Walking speed/volume linked to longevity (Harvard Health) | short_term | 60 | 76 | 4 | this_week | medium |
| **P3** | What's next after Zepbound/Ozempic: new weight-loss drugs in the pipeline | scheduled | 55 | 88 | 4 | this_week | low |
| P5 (monitor) | GammaTile Phase 3 "new standard of care" claim | monitor | — | — | — | — | — |
| P5 (monitor) | Nature exposomics / personalized medicine feature | monitor | — | — | — | — | — |
| P5 (monitor) | TikTok wellness trend → botulism warning | monitor | — | — | — | — | — |

```yaml
summary:
  total_topics: 3
  high_priority_count: 1
  immediate_actions: "Publish Salata salad dressing recall brief today; verify direct FDA.gov enforcement link before going live."
pass_to_next_layer: false
```

---

## 6. Editorial Briefs

### P1 — FDA Class I Recall: Salata Salad Dressing (Salmonella)

```yaml
brief:
  primary_headline: "FDA Issues Highest-Risk Recall for Salata Salad Dressing Over Salmonella Contamination"
  alternate_headlines:
    - "Salata Salad Dressing Recalled Nationwide: What the FDA's Class I Risk Level Means"
    - "Salmonella Risk Prompts FDA's Most Serious Recall Classification for Salad Dressing"
  topic: "FDA Class I recall — Salata salad dressing (Salmonella)"
  primary_entity: "Salata (brand) / FDA"
  search_intent: "informational + practical (what to do if you bought it)"
  angle: "Explain what Class I actually means (vs. the just-covered Class II chlorthalidone recall), symptoms to watch for, and how to check/return the product — comparison framing differentiates from pure news recap."
  why_now: "FDA escalated this recall to its highest health-risk classification 10/03; NYT and NBC both confirmed within 24–48 hours. Distinct new story, not a continuation of the Sept. 28 blood-pressure medication recall."
  integrity_flags:
    - "⚠️ Integrity note: Only 2 corroborating outlets (NYT, NBC) identified in current evidence — confirm direct FDA.gov enforcement report before publishing; breaking-recall exception applied with confidence capped Medium."
  outline:
    intro: "What happened and why Class I matters"
    sections:
      - "Class I vs. Class II vs. Class III — plain-language explainer"
      - "Which products/lot codes are affected"
      - "Salmonella symptoms and when to seek care"
      - "What to do if you have the product"
    conclusion: "Where to check for updates"
  key_data_points:
    - "FDA classified recall at highest health-risk level (Class I)"
    - "Reported via NYT 10/03/2026 and NBC News 10/02/2026"
  source_plan:
    - { publisher: "The New York Times", url: "https://www.nytimes.com/2026/10/03/health/fda-recall-salata-salad-dressing-salmonella.html", tier: 1, used_for: "Primary recall confirmation" }
    - { publisher: "NBC News", url: "https://www.nbcnews.com/video/shorts/fda-issues-highest-level-recall-of-salad-dressing-270903877823", tier: 1, used_for: "Corroboration" }
    - { publisher: "FDA.gov enforcement report", url: "[URL unverified — confirm before publish]", tier: 1, used_for: "Primary notice" }
  evidence_requirements: "Moderate — confirm lot codes/distribution states from FDA.gov directly"
  expert_sources:
    - { type: "Food safety / public health official", reason: "Contextualize Salmonella risk and handling guidance" }
  internal_links: ["(future) FDA food recall tracker", "(future) chlorthalidone BP recall piece"]
  visual_brief: "Product packaging image + FDA recall notice screenshot"
  seo:
    primary_keyword: "Salata salad dressing recall"
    supporting_keywords: ["FDA Class I recall salad dressing", "salmonella salad dressing recall 2026"]
    format: "News explainer"
    schema_markup: "NewsArticle"
    cluster: "Food safety / FDA recalls"
  discover_notes: "Specific named product + FDA classification + clear AI-query fit ('is Salata salad dressing recalled') — strong citation potential once primary FDA link is confirmed"
  key_takeaways: ["Class I = reasonable probability of serious harm or death", "Check product/lot before consuming", "Distinct from the Sept. chlorthalidone recall"]
  estimated_word_count: "700-900"
execution_notes: "Confirm direct FDA.gov link before publish — do not run on secondary sourcing alone."
confidence: medium
pass_to_next_layer: true
```

---

### P2 — Walking Speed and Longevity (Harvard Health)

```yaml
brief:
  primary_headline: "People Who Walk More — or Faster — Live Longer, New Research Finds"
  alternate_headlines:
    - "Is Walking Speed a Hidden Marker of How Long You'll Live?"
    - "Walking Pace vs. Walking Volume: Which Matters More for Longevity?"
  topic: "Walking speed/volume linked to longevity"
  primary_entity: "Walking pace / longevity research"
  search_intent: "informational + evaluative"
  angle: "Most existing coverage treats '10,000 steps' as gospel — differentiate by unpacking pace vs. volume, and what the underlying study actually measured vs. what headlines imply."
  why_now: "Harvard Health Publishing (tier-1) covered this study 10/02/2026; evergreen topic with a fresh, specific research hook."
  integrity_flags:
    - "⚠️ Integrity note: Single source in hand (Harvard Health). Confirm original journal/DOI and observational-vs-interventional study design before asserting causation."
  outline:
    intro: "The new finding in plain terms"
    sections:
      - "What the study actually measured (pace vs. steps vs. volume)"
      - "Why correlation ≠ causation in longevity research"
      - "Practical takeaways for readers who aren't daily exercisers"
    conclusion: "Bottom line: what to actually change about your walking habits"
  key_data_points: ["Faster/more walking associated with longer lifespan per Harvard Health summary — confirm original study design"]
  source_plan:
    - { publisher: "Harvard Health Publishing", url: "https://www.health.harvard.edu/heart-health/people-who-walk-more-or-walk-faster-live-longer-study-finds", tier: 1, used_for: "Primary summary" }
    - { publisher: "[Original journal — unverified]", url: "[URL unverified]", tier: 1, used_for: "Primary study citation — required before publish" }
  evidence_requirements: "Moderate-heavy — must trace to original peer-reviewed study for causation framing"
  expert_sources:
    - { type: "Exercise physiologist or geriatrician", reason: "Contextualize observational vs. causal claims" }
  internal_links: ["(future) longevity/healthspan cluster content"]
  visual_brief: "Simple pace-vs-steps infographic"
  seo:
    primary_keyword: "walking speed longevity study"
    supporting_keywords: ["does walking pace affect lifespan", "walking and longevity research"]
    format: "Evergreen explainer"
    schema_markup: "Article"
    cluster: "Aging & longevity / fitness science"
  discover_notes: "Strong AI-query fit ('does walking faster help you live longer'), but topic is commonly covered — differentiation via pace-vs-volume framing is key to standing out"
  key_takeaways: ["Volume and pace may matter independently", "Observational data — not proof of causation", "Practical minimum-effective-dose framing"]
  estimated_word_count: "900-1100"
execution_notes: "Research task: locate and cite the original study before writing — do not publish from Harvard Health summary alone."
confidence: medium
pass_to_next_layer: true
```

---

### P3 — GLP-1 Weight-Loss Drug Landscape (Concise Brief)

```yaml
brief:
  headline: "What's Next After Zepbound and Ozempic: The New Weight-Loss Drugs in the Pipeline"
  topic: "GLP-1 / next-gen weight-loss drug landscape (tirzepatide, retatrutide, CBL-514, CagriSema)"
  angle: "Rising search interest shows readers are already comparing named drugs head-to-head — build a sourced landscape explainer rather than a hype roundup, anchored to actual trial-registry status for each compound."
  key_data_points:
    - "Rising Google Trends queries: 'six month tirzepatide weight loss', 'cbl-514 weight loss injection', 'cagrisema and zepbound weight loss results', 'eli lilly retatrutide weight loss'"
    - "No corroborating news article found in current radar — search-interest signal only"
  integrity_flags:
    - "⚠️ Integrity note: No news source in hand. Every drug/efficacy claim must be sourced directly from ClinicalTrials.gov, company trial disclosures, or peer-reviewed data before publishing — do not write from search-term phrasing."
  expert_type_needed: "Endocrinologist or obesity-medicine physician"
  seo:
    primary_keyword: "new weight loss drugs 2026"
    format: "Explainer/comparison roundup"
    serp_difficulty: "Medium"
  sources:
    - { publisher: "ClinicalTrials.gov (to be sourced)", url: "[URL unverified — must be retrieved per drug before publish]" }
  estimated_word_count: "600-800"
```

---

## 7. Rejected Topics Log

| Topic | Reason |
|---|---|
| HHS SURPASS clinical trials program (+7 outlets) | `existing` — duplicate of 2026-10-01 coverage |
| NIH Long COVID antiviral trial | `existing` — duplicate of 2026-10-01 coverage |
| Chlorthalidone BP medication recall (continuing coverage) | `existing` — duplicate of 2026-09-28/09-29 coverage |
| California non-UPF food label | `existing` — duplicate of 2026-09-29 coverage |
| Stanford lymphedema drug study | `existing` — duplicate of 2026-10-01 |
| Johns Hopkins smoking/sickle cell retinopathy | `existing` — duplicate of 2026-10-02 |
| Apyx Medical Renuvion skin-quality study | `off_category` — sponsor press release, marketing-driven |
| "Wellness stacking" habit trend (Yahoo Creators) | `weak_signal` — trend_strength 24, single aggregator source |
| WSJ menopause wellness essay | `weak_signal` — trend_strength 41, single personal-essay source |
| Black patients face clinical trial barriers (St. Louis American) | `weak_signal` — single low-tier local outlet |
| Nature exposomics / personalized medicine | `other` — monitor, trend_strength 48 (just below floor), single abstract source |
| GammaTile Phase 3 brain metastases | `unverified_claim` — routed to Monitor at 02b (sponsor overstatement) |
| TikTok wellness trend → botulism warning | `unverified_claim` — no corroborating source found, search-only signal |
| New World Screwworm status | `off_category` — low audience relevance, not fresh news |
| Health insurance "giant" / fraud / policy cluster | `off_category` — political/business, excluded per category_rules |
| Local/campus wellness events (6 items) | `off_category` — local news, excluded |
| Julianne Hough wellness interview | `brand_safety` — celebrity wellness without evidence base |
| Medical Xpress mouse placenta study | `weak_signal` — animal study, low general-audience relevance |
| News-Medical TMEM63B protein study | `off_category` — too technical, no practical takeaway |
| Daily Bruin "Neural Consult" AI app | `off_category` — ed-tech, not a health claim |
| fedweek medical costs study | `off_category` — financial/insurance, not health science |
| Univ. Miami blood cancer research award | `weak_signal` — award announcement, no news substance |

---

## 8. Integrity Flags (Consolidated)

- ⚠️ **Salata recall brief**: Only 2 of the recommended 3 corroborating sources found; confirm direct FDA.gov enforcement notice before publish. Confidence capped Medium.
- ⚠️ **Walking speed/longevity brief**: Single-source (Harvard Health); original peer-reviewed study/DOI must be located and cited — do not assert causation from an observational design.
- ⚠️ **GLP-1 weight-loss brief**: Zero news corroboration — every drug-specific claim must be sourced from ClinicalTrials.gov or primary company disclosures at research stage, not from search-term phrasing.
- ⚠️ **GammaTile (Monitor, not published)**: Sponsor press release claims "new standard-of-care" from Phase 3 data — scale/certainty overstatement, requires editorial interpretation before any future scoring.

---

## 9. Run Notes

- **Recurring theme flag**: Gut health/microbiome content has run 2 consecutive days (2026-10-02, 2026-10-03). No new gut-health candidate added today — none of today's gut-health-adjacent Trends terms (bioma, mushroom coffee, align probiotics) were backed by a fresh news event. Recommend staleness check before resuming this theme.
- **Recurring theme flag**: FDA recall coverage has run 3 of the last 7 days (chlorthalidone: 09/28, 09/29, continuing 10/02). Distinguish clearly in any future piece that the Salata recall is a separate event/product category (food, not drug).
- **Data gap**: `data/deferred_topics.yaml` and `data/run_history.yaml` were not directly accessible in this session; recurrence checks above are derived from the "Recent Coverage" list supplied in-prompt rather than the actual history file. Recommend confirming file sync before next run.
- **site_url gap**: No live site configured — all duplicate/content_status checks relied on the supplied Recent Coverage list and competitor_list.yaml fallback, not true self-check.
- **Tool status**: All required/recommended tools (SerpAPI News/Search/Trends) reported available via live pre-fetch; no outages this run.